For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
REGULATORY
Japan Cabinet OKs Bill to Amend PMD Law
Japan’s Cabinet on March 19 approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Law, aiming to get it enacted by the Diet in the current ordinary parliamentary session through to June. The bill encompasses a wide range…
To read the full story
Related Article
- PMD Amendment Bill Put under Continued Diet Review
June 28, 2019
- PMD Bill Clears LDP Review, Cabinet OK Slated for March 19
March 18, 2019
- MHLW Seeks Opposition Party Understanding on Removal of Officer Change Order Provision from Amendment Bill for PMD Law
March 15, 2019
- Dismissal Order Provision Erased from PMD Law Amendment Bill
March 14, 2019
- MHLW Likely to Tweak PMD Law Amendment Bill as Lawmaker Frowns on Order to Change Pharmaceutical Affairs Officer
March 13, 2019
- LDP Wraps Up Review on Bill to Amend PMD Law; Cabinet OK Eyed in Mid-March
March 8, 2019
- LDP Panels Approve Proposal to Promote Regulatory Harmonization, Improve Access in Asia
March 8, 2019
REGULATORY
- Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
- Pharma Industry Makes Plea to Komeito to Scrap Off-Year Revisions
December 2, 2024
- Japan Partially Eases Rule for Use of Abortion Pill Mefeego
December 2, 2024
- MOF Panel Wants Prioritized Budgeting for Drug Costs: Subcommittee Acting Chair
December 2, 2024
- MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…